Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma.
Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. Kaseb AO, et al. Among authors: yao jc. J Hepatocell Carcinoma. 2021 Sep 9;8:1129-1145. doi: 10.2147/JHC.S318865. eCollection 2021. J Hepatocell Carcinoma. 2021. PMID: 34527608 Free PMC article.
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.
Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC. Kaseb AO, et al. Among authors: yao jc. Onco Targets Ther. 2016 Feb 15;9:773-80. doi: 10.2147/OTT.S91977. eCollection 2016. Onco Targets Ther. 2016. PMID: 26929648 Free PMC article.
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma.
Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Mahvash A, et al. Among authors: yao jc. J Hepatocell Carcinoma. 2016 Feb 5;3:1-7. doi: 10.2147/JHC.S62261. eCollection 2016. J Hepatocell Carcinoma. 2016. PMID: 27574586 Free PMC article.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States.
Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO. Al-Shamsi HO, et al. Among authors: yao jc. Oncology. 2017;93(4):233-242. doi: 10.1159/000455957. Epub 2017 Jul 6. Oncology. 2017. PMID: 28683459 Free PMC article.
314 results